ERBB2 and inflammatory breast carcinoma: Novel treatments are also being implemented for IBC; however, this has been extrapolated from studies investigating non-IBC, such as addition of pembrolizumab in neoadjuvant and metastatic setting for triple-negative IBC and the use of adjuvant T-DM1 for HER2+ IBC (20).